ERES East Resources Acquisition Company

Top 10 Global Pharmaceutical Company Awards $1.4 Million Study to eResearchTechnology for Cardiac Safety Monitoring and Information Distribution Services Marks 12th Thorough Phase I ECG Study Awarded to eRT in 2Q2004 PHILADELPHIA, June 30 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT) (NASDAQ:ERES), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has received an agreement for more than $1.4 million in cardiac safety monitoring and services from a top 10 global pharmaceutical organization for one of its drug candidates in clinical development. The agreement covers an extensive Phase I study for which eRT is providing comprehensive support, including the provision, training and ongoing assistance required for effective use of digital 12-lead equipment designed to collect cardiac safety data that is subsequently provided to eRT for analysis. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. "We are delighted to have been selected by this global industry leader to provide comprehensive Thorough Phase I ECG Study services for this important compound," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "As the twelfth Thorough Phase I Study awarded to eRT in the second quarter, this trial is fitting to mark an important milestone for eRT in our efforts to enhance the value we deliver to the new drug development industry. eRT's unmatched capacity and throughput, combined with extensive medical, operational, and project management resources, provide the scalability required to meet the growing demand for cardiac safety services in both the Thorough Phase I ECG Study area and for massively distributed global trials included in today's later phase development programs." Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. The sponsor may cancel this agreement at its sole discretion. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci of eResearchTechnology, +1-908-203-6473, or Matt Hayden of Hayden Communications, +1-858-456-4533, for eResearchTechnology Web site: http://www.ert.com/

Copyright